Roche Seeks Leading Role For PD-L1 Checkpoint Inhibitor In Bladder Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
In a just-released ASCO abstract, Roche/Genentech’s MPDL3280A demonstrates 50% objective response rate in biomarker+ patients and no new safety signals in Phase I bladder cancer study. Unmet need and a strong efficacy signal support prioritizing this new indication, says Genentech’s Dan Chen.
You may also be interested in...
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Can-Fite Plans Phase III For Namodenoson, Despite Liver Cancer Trial Failure
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.